Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jun 11, 2009


Title: Snap-Back Primers and Detectable Hairpin Structures

Number: 20090142752

Filed: Oct. 3, 2007

Lead Inventor: Jeff Hall, Third Wave Technologies

The invention, the patent application's abstract states, "provides methods, compositions, and kits comprising snap-back primers used for forming 3' hairpin structures, 5' hairpin structures, and double-hairpin structures. The hairpin structures may be used for detecting target sequences … such as [a] small RNA target sequence, for detecting polymorphisms in target sequences … such as polymorphisms located near the 5' or 3' ends of the target sequence, or other nucleic acid characterization methods.

"In certain embodiments, the hairpin structures form invasive cleavage structures … which may be cleaved by structure-specific enzymes in order to detect the presence or absence of a particular nucleotide or nucleotide sequence," the abstract adds.

Title: Nucleic Acid Agents for Down-Regulating H19 and Methods of Using the Same

Number: 20090143321

Filed: July 6, 2006 PCT Filed: July 6, 2006

Lead Inventor: Avraham Hochberg, Biocancell

The invention comprises "isolated oligonucleotides capable of down-regulating a level of H19 mRNA in cancer cells," the patent application's abstract states. "Articles of manufacture comprising agents capable of down-regulating H19 mRNA in combination with an additional anti-cancer treatment are disclosed, as well as methods of treating cancer by administering same."

Title: Cell-Transfecting Formulations of Small Interfering RNA-Related Compositions and Methods of Making and Use

Number: 20090143322

Filed: March 21, 2008

Lead Inventor: Timothy Burkoth, Chiron

The patent application, its abstract states, claims "compositions incorporating small interfering ribonucleic acid and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells."

Also claimed are methods of making and using the compositions, the abstract notes.

Title: Compositions and Methods for Inhibiting Expression of a Gene from Ebola

Number: 20090143323

Filed: March 25, 2008

Lead Inventor: Sina Bavari, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the Ebola virus," the patent application's abstract states.

Titles: RNA Interference-Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid

Numbers: 20090143324, 20090143325

Filed: Sept. 3 & 4, 2008

Lead Inventor:
James McSwiggen, Sirna Therapeutics (Merck)

The inventions relate to "compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid molecules," the patent applications' abstracts state. They also relate to "compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference using small nucleic acid molecules."

In particular, the inventions feature small nucleic acid molecules … and methods used to modulate the expression of interleukin and/or interleukin receptor genes, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, and IL-27 genes, and IL-1R, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, IL-15R, IL-16R, IL-17R, IL-18R, IL-19R, IL-20R, IL-21R, IL-22R, IL-23R, IL-24R, IL-25R, IL-26R, and IL-27R, the abstracts note.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.